MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals Inc. reported strong net sales revenue for LIVMARLI, amounting to $64.1 million in Q4 2024, which reflects an 8.4% quarterly growth and a substantial 54.5% increase year-over-year. The company expects continued sales growth from both the ALGS and PFIC indications, projecting a steady increase in top-line contributions throughout 2025, particularly as they expand their product offerings and capitalize on recent FDA approvals. Furthermore, positive clinical data supporting the efficacy of volixibat and upcoming milestones position Mirum as a cash-flow positive, commercial-stage entity with significant potential for future revenue growth.

Mirum Pharmaceuticals faces several significant risks that contribute to a negative outlook on its stock, including potentially disappointing sales growth of Livmarli and volixibat, failure to secure further regulatory approvals, and the possibility of failed or inconclusive trial results. Additionally, the company reported a substantial fiscal year 2024 net loss of $87.9 million, driven largely by elevated R&D and SG&A expenses, which raises concerns regarding its ability to fund operations without diluting shareholder value. Furthermore, as Mirum seeks to differentiate its pipeline candidates amid intense competition, any commercial setbacks may prolong its path to profitability and exacerbate its financial challenges.